Dupont Hervé, Gaillot Olivier, Goetgheluck Anne-Sophie, Plassart Claire, Emond Jean-Philippe, Lecuru Marion, Gaillard Nicolas, Derdouri Sarah, Lemaire Baptiste, Girard de Courtilles Marion, Cattoir Vincent, Mammeri Hedi
Département d'Anesthésie-Réanimation, CHU Amiens-Picardie, Amiens, France, and INSERM U1088, Université de Picardie Jules Verne, Amiens, France.
Service de Bactériologie, Pôle de Biologie Pathologie Génétique du CHU de Lille, Lille, France.
Antimicrob Agents Chemother. 2015 Oct 19;60(1):215-21. doi: 10.1128/AAC.01559-15. Print 2016 Jan.
An interregional surveillance program was conducted in the northwestern part of France to determine the prevalence of carbapenem-nonsusceptible Enterobacteriaceae (CNSE) isolates and their susceptibility to ceftazidime-avibactam and aztreonam-avibactam combinations. Nonduplicate CNSE clinical isolates were prospectively collected from six hospitals between June 2012 and November 2013. MICs of ceftazidime and aztreonam, alone or combined with a fixed concentration of avibactam (4 μg/ml), and those of carbapenems (comparator agents) were determined. MICs of ertapenem in combination with phenylalanine arginine-naphthylamide dihydrochloride (PAβN) were also determined to assess active efflux. Genes encoding carbapenemases, plasmid-mediated AmpC enzymes, extended-spectrum β-lactamases (ESBLs), and major outer membrane proteins (OMPs) were amplified and sequenced. OMPs were also extracted for SDS-PAGE analysis. Among the 139 CNSE isolates, mainly Enterobacter spp. and Klebsiella pneumoniae, 123 (88.4%) were ertapenem nonsusceptible, 12 (8.6%) exhibited reduced susceptibility to all carbapenems, and 4 Proteeae isolates (2.9%) were resistant to imipenem. Carbapenemase production was detected in only two isolates (producing OXA-48 and IMI-3). In contrast, OMP deficiency, in association with AmpCs and/or ESBLs (mainly CTX-M-9, SHV-12, and CTX-M-15), was largely identified among CNSE isolates. The ceftazidime-avibactam and aztreonam-avibactam combinations exhibited potent activity against CNSE isolates (MIC50/MIC90, 1/1 μg/ml and 0.5/0.5 μg/ml, respectively) compared to that of ceftazidime and aztreonam alone (MIC50/MIC90, 512/512 μg/ml and 128/512 μg/ml, respectively). This study reveals the in vitro activity of ceftazidime-avibactam and aztreonam-avibactam combinations against a large collection of porin-deficient enterobacterial isolates that are representative of the CNSE recovered in the northern part of France.
在法国西北部开展了一项区域间监测计划,以确定碳青霉烯类不敏感肠杆菌科(CNSE)分离株的流行情况及其对头孢他啶-阿维巴坦和氨曲南-阿维巴坦联合制剂的敏感性。在2012年6月至2013年11月期间,前瞻性收集了来自六家医院的非重复CNSE临床分离株。测定了头孢他啶和氨曲南单独或与固定浓度阿维巴坦(4μg/ml)联合使用时的最低抑菌浓度(MIC),以及碳青霉烯类药物(对照药物)的MIC。还测定了厄他培南与苯丙氨酸精氨酸萘酰胺二盐酸盐(PAβN)联合使用时的MIC,以评估主动外排情况。对编码碳青霉烯酶、质粒介导的AmpC酶、超广谱β-内酰胺酶(ESBL)和主要外膜蛋白(OMP)的基因进行扩增和测序。还提取了OMP进行SDS-PAGE分析。在139株CNSE分离株中,主要为肠杆菌属和肺炎克雷伯菌,123株(88.4%)对厄他培南不敏感,12株(8.6%)对所有碳青霉烯类药物的敏感性降低,4株变形杆菌属分离株(2.9%)对亚胺培南耐药。仅在两株分离株中检测到碳青霉烯酶产生(产生OXA-48和IMI-3)。相比之下,在CNSE分离株中大量发现了与AmpC和/或ESBL(主要是CTX-M-9、SHV-12和CTX-M-15)相关的OMP缺陷。与单独的头孢他啶和氨曲南相比,头孢他啶-阿维巴坦和氨曲南-阿维巴坦联合制剂对CNSE分离株表现出强大的活性(MIC50/MIC90分别为1/1μg/ml和0.5/0.5μg/ml)(头孢他啶和氨曲南的MIC50/MIC90分别为512/512μg/ml和128/512μg/ml)。本研究揭示了头孢他啶-阿维巴坦和氨曲南-阿维巴坦联合制剂对大量缺乏孔蛋白的肠杆菌分离株的体外活性,这些分离株代表了在法国北部分离出的CNSE。